Want to see GALT full AI Analyst Report?
GALT Stock Chart & Stats
$3.47
-$0.09(-2.59%)
At close: 4:00 PM EDT
$3.47
-$0.09(-2.59%)
Day’s Range― - ―
52-Week Range$2.03 - $7.13
Previous Close$3.42
Volume305.15K
Average Volume (3M)982.04K
Market Cap
$229.84M
Enterprise Value$307.34
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$135.72M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Aug 17, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding65,856,895
10 Day Avg. Volume678,820
30 Day Avg. Volume982,042
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside217.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Phase 3 AlignmentThe FDA Type C meeting produced formal alignment on endpoints, design and a traditional full‑approval pathway for a single confirmatory Phase 3 study. This materially reduces regulatory uncertainty, strengthens trial credibility, and makes the program more partnerable over the medium term.
Improving Cash Burn TrendTrailing cash flow trends show meaningful improvement versus the prior year, indicating tighter expense control and operational discipline. A declining cash burn rate lengthens runway and lowers near‑term financing urgency, improving the firm's ability to execute a Phase 3 plan or negotiate better partner deals.
Focused Galectin-3 ExpertiseA clear scientific focus on galectin‑3 gives the company a specialized R&D platform and clinical development experience with belapectin in fibrosis/NASH. If the mechanism proves clinical benefit, this targeted expertise supports durable differentiation within a large, unmet therapeutic area.
Bears Say
No Revenue; Persistent LossesThe company has no operating revenue and sizeable trailing losses, meaning it cannot self‑fund development. Persistent negative earnings and cash flow create ongoing dilution or funding risk, constraining strategic optionality and making long‑term program continuity contingent on external capital.
Weak Balance Sheet LeverageDeeply negative equity paired with material debt limits financial flexibility and increases refinancing risk. A leveraged balance sheet restricts the company's ability to absorb setbacks, negotiate favorable partner terms, or self‑fund a costly confirmatory Phase 3 study without significant dilution or onerous covenants.
Dependence On Partners/financingDespite FDA alignment, the firm explicitly needs strategic or financial partners to advance Phase 3. Reliance on external funding/alliances introduces execution risk, potential delays, and dilution; partner negotiations and timelines are structural constraints on program progression.
Galectin Therapeutics News
GALT FAQ
What was Galectin Therapeutics (GALT)’s price range in the past 12 months?
Galectin Therapeutics (GALT) lowest stock price was $2.02 and its highest was $7.13 in the past 12 months.
What is Galectin Therapeutics (GALT)’s market cap?
Galectin Therapeutics (GALT)’s market cap is $229.84M.
When is Galectin Therapeutics (GALT)’s upcoming earnings report date?
Galectin Therapeutics (GALT)’s upcoming earnings report date is Aug 17, 2026 which is in 17 days.
How were Galectin Therapeutics (GALT)’s earnings last quarter?
Galectin Therapeutics (GALT) released its earnings results on May 15, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Galectin Therapeutics (GALT) overvalued?
According to Wall Street analysts Galectin Therapeutics (GALT)’s price is currently Undervalued.
Does Galectin Therapeutics (GALT) pay dividends?
Galectin Therapeutics (GALT) does not currently pay dividends.
What is Galectin Therapeutics (GALT)’s EPS estimate?
Galectin Therapeutics (GALT)’s EPS estimate is -0.09.
How many shares outstanding does Galectin Therapeutics (GALT) have?
Galectin Therapeutics (GALT) has 65,856,895 shares outstanding.
What happened to Galectin Therapeutics (GALT)’s price movement after its last earnings report?
Galectin Therapeutics (GALT) reported an EPS of -$0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.66%.
Which hedge fund is a major shareholder of Galectin Therapeutics (GALT)?
Currently, no hedge funds are holding shares in GALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (217.00% Upside)
$11.00 (217.00% Upside)
Blogger Sentiment
Bullish
GALT Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
65.40%
Trailing 12-Months
Company Description
Galectin Therapeutics (GALT)
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
GALT Stock 12 Month Forecast
Average Price Target
$11.00
▲(217.00% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
26.04% Insiders
3.90% Mutual Funds
0.85% Other Institutional Investors
62.93% Public Companies and
Individual Investors